- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data | 2 | Insider Monkey | ||
| 10.12.25 | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | 3 | GlobeNewswire (USA) | ||
| 12.11.25 | Earnings Call: Journey Medical meldet Umsatzwachstum für Q3 2025 und stellt positives EBITDA in Aussicht | 6 | Investing.com Deutsch | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Journey Medical GAAP EPS of -$0.09, revenue of $17.6M | 2 | Seeking Alpha | ||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 175 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| 12.11.25 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.11.25 | Insights into Journey Medical's Upcoming Earnings | 13 | Benzinga.com | ||
| 05.11.25 | Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea | 2 | RTTNews | ||
| 24.10.25 | Journey Medical's Emrosi shows superior efficacy for rosacea | 1 | Investing.com | ||
| 26.09.25 | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09.25 | Summers Value Partners' Update on Journey Medical (DERM) | 6 | Insider Monkey | ||
| 28.08.25 | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08.25 | H.C. Wainwright stuft Journey Medical mit "Kaufen" ein - Rosacea-Medikament Emrosi als entscheidender Faktor | 9 | Investing.com Deutsch | ||
| 25.08.25 | H.C. Wainwright initiates Journey Medical stock with Buy rating on Emrosi potential | 2 | Investing.com | ||
| 20.08.25 | Journey Medical setzt auf Rosacea-Mittel Imrozi für Profitabilitätswende | 5 | Investing.com Deutsch | ||
| 13.08.25 | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 5 | Seeking Alpha | ||
| 12.08.25 | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 12.08.25 | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 580 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| 12.08.25 | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,770 | +0,35 % | mRNA Patentstreit: Bayer zieht BioNTech, Pfizer und Moderna vor Gericht | © Foto: Juan Vega - EUROPA PRESSBayer erhebt schwere Patentvorwürfe gegen die Hersteller der erfolgreichsten Corona-Impfstoffe. Im Zentrum steht eine mRNA-Technologie aus den 1980er-Jahren.Der Agrar-... ► Artikel lesen | |
| GILEAD SCIENCES | 103,44 | -0,12 % | GSK: Erfolg in Hepatitis B - wird Gilead nun abgehängt? | GlaxoSmithKline hat positive Ergebnisse aus den beiden entscheidenden Phase-3-Studien seines experimentellen Medikaments Bepirovirsen zur Behandlung von chronischer Hepatitis B vorgelegt. Noch im laufenden... ► Artikel lesen | |
| ELI LILLY | 932,60 | +0,14 % | Lilly und Viking Therapeutics abgestraft: Wegovy als Pille zerlegt den Markt - Novo-Aktie haussiert | © Foto: Steffen Trumpf/dpaDer Marktstart der Wegovy-Pille bringt Bewegung in den GLP-1-Sektor. Während Novo profitiert, machen Investoren bei Wettbewerbern Kasse. Novo Nordisk hat in den USA die Wegovy-Tablette... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 405,00 | +0,46 % | $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today | ||
| EYEPOINT | 14,930 | +1,88 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 | - Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 10,900 | -2,68 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 170,00 | 0,00 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 136,05 | -1,09 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer | Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions
... ► Artikel lesen | |
| OPKO HEALTH | 1,152 | -1,64 % | OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth | ||
| UNITED THERAPEUTICS | 424,70 | +0,83 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| ROYALTY PHARMA | 35,000 | +1,33 % | Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics | SOUTH SAN FRANCISCO (dpa-AFX) - Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics' remaining royalty interest in Roche's Evrysdi. The transaction... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,585 | +0,98 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies | ||
| BRIDGEBIO PHARMA | 63,42 | +0,13 % | Oppenheimer bestätigt "Outperform"-Rating für BridgeBio nach neuen Onkologie-Daten | ||
| TG THERAPEUTICS | 24,765 | -5,42 % | TG Therapeutics, Inc.: TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 18,700 | +1,08 % | Bank of America discloses stake in Avadel Pharmaceuticals |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 7,310 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.